An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

NCT07668453 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

BIOLOGICAL: Adebrelimab
DRUG: gemcitabine
DRUG: Albumin-Bound Paclitaxel /nab-Paclitaxel

Sponsor

The First Affiliated Hospital with Nanjing Medical University